AUS
NZ
UK
CA
USA
IND
Highlights
- ACCC grants approval for Sigma Healthcare and Chemist Warehouse merger.
- Court-enforceable undertaking ensures fair market competition.
- Chemist Warehouse to enter ASX without an IPO fanfare.
The Australian Competition and Consumer Commission (ACCC) has granted Sigma Healthcare (ASX:SIG) approval to proceed with its merger with Chemist Warehouse, creating a significant development in the pharmacy sector. This approval enables Sigma Healthcare to reverse list Chemist Warehouse on the ASX, paving the way for one of the year’s most highly anticipated market entries. Instead of a traditional IPO, this reverse listing means Chemist Warehouse will debut on the ASX without the usual initial public offering buzz.
As part of the agreement, both Sigma Healthcare and Chemist Warehouse accepted a court-enforceable undertaking directed by the ACCC. This undertaking aims to maintain a fair competitive landscape, allowing pharmacies currently in long-term contracts with Sigma to switch wholesalers if desired. ACCC's decision reflects its confidence in existing market competition, supported by other pharmaceutical distributors like Australian Pharmaceutical Industries (API), EBOS Group, and Clifford Hallam Healthcare (CH2), who are contracted to supply PBS-listed medications under Commonwealth agreements.
Gina Cass-Gottlieb, ACCC Chair, highlighted that the merger is unlikely to reduce competition substantially. The ACCC concluded that, with competitors like API, EBOS, and CH2 actively participating in the market, the combined Sigma and Chemist Warehouse entity would still face effective competition across the pharmacy supply chain.
Despite ACCC’s approval, the merger has met resistance. The Australian Pharmacy Guild recently voiced its opposition, arguing that the merger should not proceed. However, the ACCC has emphasized that Sigma’s customers retain the freedom to switch wholesalers, ensuring the combined entity will not monopolize the market.
In an official statement, the ACCC also noted changes in the regulatory environment affecting the pharmacy industry. These changes mean that even though Chemist Warehouse and Sigma are combining forces, their influence over Sigma’s banner pharmacies may differ from Chemist Warehouse's current level of influence over its franchisees. This shift aligns with ACCC's commitment to preserving competition and preventing any single player from gaining undue influence.
According to ACCC, there will be “effective competition at all levels of the pharmacy supply chain, capable of constraining a combined Sigma and Chemist Warehouse.” This statement reflects the regulator’s view that, despite the merger, a fair and competitive market environment will persist. Following the ACCC’s announcement, Sigma Healthcare shares last traded at AUD 1.95 on the ASX, underscoring investor interest in this significant market event.
